"Late-Stage Development first quarter revenues grew 16.8% year-on-year to $373 million. Central laboratories and clinical development grew 20% and 18%, respectively, which more than offset a decline ...
(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure. (2) Consists of gain on sale of investments $16,400 and asset impairment charges ...
Troy Segal is an editor and writer. She has 20+ years of experience covering personal finance, wealth management, and business news. David Kindness is a Certified Public Accountant (CPA) and an expert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results